Share this Job

Senior Technician - Stem Cell Culture

Req ID:  42438

Saffron Walden, ESS, GB, cb10 1xl

For 70 years, Charles River employees have worked together to assist in the discovery, development and safe manufacture of new drug therapies. When you join our family, you will have a significant impact on the health and well-being of people across the globe. Whether your background is in life sciences, finance, IT, sales or another area, your skills will play an important role in the work we perform. In return, we’ll help you build a career that you can feel passionate about.

Job Summary

Due to enhanced client demand, we are looking for an experienced stem cell technician to join our stem cell culture team.


In this lab based role, you will join our established team of stem cell experts, supplying and quality controlling cells for assays and characterization to aid our clients' drug discovery programs. 


You will have a degree or equivalent experience, together with significant practical experience in culturing and differentiation of hES and iPS cells, ideally with a background in neurodegenerative disorders.


You will have outstanding aseptic technique, an excellent attention to detail, and a positive can-do attitude. 


Most importantly, you will have a passion for seeing the results of your work influencing ongoing drug discovery programs.


Candidates with a demonstrated expertise in isolation and culturing of primary cells, recombinant cell line generation or preparation of cell lines for high throughput screening will be at a significant advantage.


This position requires joining a weekend working rota (approximately 2 half days every month) - additionally, candidates who would be willing to consider a non-traditional working pattern are welcomed.


Applicants must have the right to work for any company in the UK.




About Discovery
Discovery from Charles River is industry-proven in the successful development of novel therapies, with over 320 patents and 74 preclinical drug candidates delivered to our sponsors in the past 17 years. Backed by more than 650 scientists, our comprehensive, integrated portfolio employs the latest technology and platforms to provide chemistry, biology, and pharmacology services that support clients from the earliest stages of hit identification all the way through to IND. Our client-focused, collaborative approach creates true partnerships that anticipate challenges, overcome obstacles, and move us forward together on the journey of getting new drugs to market.


About Charles River
Charles River is an early-stage contract research organization (CRO). We have built upon our foundation of laboratory animal medicine and science to develop a diverse portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP, to support clients from target identification through preclinical development. Charles River also provides a suite of products and services to support our clients’ clinical laboratory testing needs and manufacturing activities. Utilizing this broad portfolio of products and services enables our clients to create a more flexible drug development model, which reduces their costs, enhances their productivity and effectiveness to increase speed to market.


With over 13,000 employees within 80 facilities in 23 countries around the globe, we are strategically positioned to coordinate worldwide resources and apply multidisciplinary perspectives in resolving our client’s unique challenges.  Our client base includes global pharmaceutical companies, biotechnology companies, government agencies and hospitals and academic institutions around the world.


At Charles River, we are passionate about our role in improving the quality of people’s lives. Our mission, our excellent science and our strong sense of purpose guide us in all that we do, and we approach each day with the knowledge that our work helps to improve the health and well-being of many across the globe. We have proudly supported the development of 80% of the drugs approved by the FDA in 2017.


For more information, please visit